Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.

@article{SchmitzWinnenthal2015AntiangiogenicAO,
  title={Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.},
  author={Friedrich Hubertus Schmitz-Winnenthal and Nicolas Hohmann and Andreas G. Niethammer and Tobias Friedrich and Heinz Lubenau and Marco Springer and Klaus M Breiner and Gerd Mikus and J{\"u}rgen Weitz and Alexis B. Ulrich and Markus W. B{\"u}chler and Frank Pianka and U Klaiber and Markus K Diener and Christine Leowardi and Simon Schimmack and Leila Sisic and Anne-Valerie Keller and Ruhan Koc and Christoph Springfeld and Philipp Knebel and Thomas Schmidt and Yingzi Ge and Mariana Bucur and Slava Stamova and Lilli Podola and Walter E. Haefeli and Lars Grenacher and Philipp Beckhove},
  journal={Oncoimmunology},
  year={2015},
  volume={4 4},
  pages={e1001217}
}
VEGFR-2 is expressed on tumor vasculature and a target for anti-angiogenic intervention. VXM01 is a first in kind orally applied tumor vaccine based on live, attenuated Salmonella bacteria carrying an expression plasmid, encoding VEGFR-2. We here studied the safety, tolerability, T effector (Teff), T regulatory (Treg) and humoral responses to VEGFR2 and… CONTINUE READING